Liver transplant and autoimmune liver diseases: An up-to-date review

Read full text Summarise with VIRAT
Authors: João P C Freire, Caio Ferraz Lopes, Pedro H M Lima, Lucas Dias Feliciano, Fabrício Freire de Melo
Cited by: 0
References: 108

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Autoimmune liver diseases, encompassing autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis, are chronic immune-mediated disorders that are uncommon but clinically significant due to their progressive nature, diagnostic complexity, and limited treatment options. These conditions may evolve into advanced fibrosis, cirrhosis, or liver failure, and liver transplantation, while life-saving, does not eliminate the underlying immune dysregulation and introduces risks of disease recurrence and complications from chronic immunosuppressive therapy, such as osteoporosis, infections, and metabolic disorders. Autoimmune hepatitis is characterized by hepatocellular inflammation and fibrosis associated with autoantibodies, including antinuclear antibodies, smooth muscle antibodies, anti–liver kidney microsomal type 1 antibodies, and anti–soluble liver antigen/liver pancreas antibodies, as well as aberrant B and T lymphocyte activity. Standard therapy relies on corticosteroids combined with azathioprine, but novel approaches are under investigation, including rituximab, zetomipzomib, and toll-like receptor 4 antagonists. Primary biliary cholangitis is marked by autoimmune-mediated destruction of small bile ducts, commonly associated with antimitochondrial antibodies, gp210, and sp100 antibodies. Ursodeoxycholic acid (UDCA) is the cornerstone of therapy, although up to 40% of patients show incomplete response, prompting interest in obeticholic acid, bezafibrate, peroxisome proliferator-activated receptor agonists, and setanaxib. Primary sclerosing cholangitis involves progressive intra- and extrahepatic duct fibrosis, associated with IgG4, perinuclear anti-neutrophil cytoplasmic antibodies, and an increased cancer risk, with emerging therapies such as norUDCA, farnesoid X receptor agonists, anti-tumor necrosis factor, anti-integrin agents, and autologous stem cell transplantation.

Fields of Study & Subjects

Liver Diseases and Immunity Organ Transplantation Techniques and Outcomes Pediatric Hepatobiliary Diseases and Treatments

Publication details

Journal / source
World Journal of Gastrointestinal Surgery
Volume
18
Issue
3
Publication date
26 March 2026
Language
EN